Aim(s): Dihydropyrimidine dehydrogenase (DPD) deficiency can lead to severe toxicity following 5FU or capecitabine (CAP) treatment. Uracil (U) can be used as a probe to determine the systemic DPD activity. This study was performed to assess the sensitivity and specificity of an U loading dose for detecting DPD deficiency.
Limited sampling strategy Chapter 6 6 IntroductIon 5-Fluorouracil (5-FU) is extensively metabolized by dihydropyrimidine dehydrogenase (DPD) into fluorodihydrouracil (FDHU) [1] [2] [3] [4] . Reduced activity of DPD will result in altered 5-FU pharmacokinetics (PK) [5] [6] [7] and the increased exposure to 5FU can cause severe side effects [8] . Pre-emptive testing followed by dose reduction for patients with DPD deficiency might prevent these severe side effects [7] . Despite the fact that several tests are available to screen for DPD deficiency, only a few are implemented on a broad scale in a pre-emptive setting [9] . Previously, we showed that administration of an oral loading dose of U allows the identification of patients with normal DPD activity and DPD deficient patients [10] .
However, the intensive blood sampling scheme that was used previously is a major drawback for a pre-emptive setting [10] . Quantitative compartmental modeling has proven to be a sensitive tool in describing the mechanisms involved in PK [7] . The object of this study was to develop a limited sampling strategy, to detect decreased U elimination in patients with a DPD deficiency and to perform a more in-depth quantitative compartmental pharmacokinetic analysis of U plasma concentrations.
MAterIAls And Methods

Patients and study design
Patients were included in 10 hospitals in The Netherlands between August 2006 and December 2013. The study population consisted of cancer patients who suffered from CTC grade III or IV toxicity after the first or second cycle of treatment schedules containing 5-FU or capecitabine. Since the incidence of DPD deficiency is relatively (3-5%) low in the Caucasian population [2] , only patients with toxicity were included in order to increase the likelihood to find DPD deficient patients. DPD activity in PBMCs [11] was determined and patients were divided in 2 groups: patients with DPD activity in PBMCs < 5 nmol mg -1 *h -1 were considered deficient (deficient group) while patients with activity ≥ 5 nmol mg -1 *h -1 were classified as normal with respect to DPD status (normal group, mean ± SD controls: 9.9 ± 2.8 nmol mg ). Coefficient of variation (CV) and limit of detection (LOD) of this assay were previously described [11] . No discrimination was made between tumour type or adjuvant treatment versus metastatic disease. The study flow diagram is displayed in 
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In all participants, U 500 mg m -2 as a loading dose was administered orally followed by blood sampling as described before by using 2 different sampling schemes [10] . The U test dose was administered in the morning around 08:00 after an overnight fast to minimize variance caused by possible circadian effects off DPD activity and food intake. Plasma concentrations following the loading dose of U and its metabolite dihydrouracil (DHU) were determined by high performance liquid chromatography (HPLC) [12] . CV of U were 4.8% (4 mg l for both U and DHU. In the deficient group, genetic analysis of DPYD was performed by PCR amplification of all 23 coding exons and flanking intronic regions followed by sequence analysis, essentially as described before [8] . In all patients, prior before the U loading dose was administered, endogenous concentrations of U, thymine, DHU, dihydrothymine, N-carbamyl-ß-alanine and N-carbamyl-ß-aminoisobutyric acid in plasma were determined using reversed-phase HPLC combined with electrospray tandem mass spectrometry [13, 14] . CV and LOD of this method were described before [13] . Values of creatinine, alanine transaminase (ALAT), gamma-glutamyl transpeptidase (Gamma-GT) and white blood cell count measured before the occurrence of fluoropyrimidine related toxicity of all subjects were collected. Toxicity data was collected and scored by the local investigator of each participating hospital according to the Common Toxicity Score (CTC) version 3. The CTC was scored for the typical fluoropyrimidine side effects diarrhea, stomatitis, neutropenia and hand-foot syndrome. The cumulative CTC score of each individual was obtained by calculating the sum of all CTC ratings. The mean cumulative CTC score of both study groups was used to compare the toxicity burden between both groups. The study protocol was approved by the Ethics Review Committee of the Martini Hospital Groningen in the Netherlands and all patients gave written informed consent.
Pharmacokinetic analysis
All patients received orally 500 mg m -2 U after which blood was taken prior after intake. A full sampling scheme (FSS) in which blood samples were collected at 0, 15, 30, 45, 60, 80, 100, 120, 150, 180 and 240 minutes was applied in the first 10 patients of both study groups.
A limited sampling scheme (LSS) in which blood was taken prior to the intake and at 60
and 120 minutes was applied to all other subjects in both study groups. The time points of the LSS were determined as the optimal LSS points based on results of an interim analysis as previously reported [10] . The pharmacokinetic parameters that were investigated were the U concentration at t = 120 minutes, the U/DHU ratio at t = 120 min and the V max value derived from a pharmacokinetic U model. To calculate the V max of both study groups, the following approach was used: based on U and DHU concentrations measured in the blood samples of the FSS of both study groups, a population one-compartment model (EURMIX model) with Michaelis-Menten elimination PK was developed with the 'KINPOP module' of MwPharm version 3.50 (Mediware, Groningen, the Netherlands) [15] . The elimination parameters were: Michaelis-Menten constant (K M ), V max , the aparent volume of the central or plasma compartment in a one compartment model (V1) and absorption constant (ka).
Pharmacokinetic parameters were assumed to be distributed log-normally. Since no data is available with respect to the oral bioavailability of U, we assumed that 100% of the administered dose was absorbed from the gastrointestinal tract since the gastrointestinal absorption of U is a fast pharmacokinetic first order process [16] .
The same principle was used to develop population models for the DPD deficient (EURDEF model) and DPD normal (EURNOR model) study groups. The EURMIX model was used to calculate the V max of all individual subjects based on the LSS, with the use of an iterative two stage Bayesian (ITBS) procedure [15, 17] . To establish the performance of the LSS, the FSS data were used for an explorative internal validation. Using the FSS data, V max,FSS values were calculated with the EURMIX model. Subsequently in the same dataset V max,LSS values were calculated with the EURMIX model using only U and DHU data of the t = 60 and 120 minutes samples. Both V max,FSS and V max,LSS were compared by correlation analysis and the performance of the LSS was considered valid if the mean prediction error was < 5% and the root mean square error (RMSE) was < 10%.
statistical analysis
Normal distribution of data was tested by performing the Shapiro-Wilk test. Comparison of parameters between the two study groups was performed by using the two-sample Student's t-test and Chi square analysis. Receiver operating characteristic (ROC)-curves were used to determine the cut-off levels bases of sensitivity (true positive rate) and specificity (true negative rate). The level of significance was set at p ≤ 0.05. Analysis was performed by using the Statistical Package for the Social Sciences (SPSS), version 19 (IBM SPSS Inc., Chicago, IL, USA).
Limited sampling strategy
Chapter 6 6 results
In total 47 cancer patients aged > 18 year were included, 19 in the DPD deficient group and 28 in the DPD normal group based upon DPD enzyme measurement in PBMCs. Because several patients were included simultaneously in different hospitals after starting the study, the FSS was applied to more than 10 patients in each study group. In the deficient and normal group the FSS was performed in 14 resp 12 patients. The patient characteristics are displayed in Table 6 .1.
Of all characteristics, only the DPD activity in PBMCs differed significantly between the two groups (p < 0.05). Weight, length, age, liver-and renal function did not differ significantly.
From measurement of the endogenous pyrimdine metabolites, we found that none of the metabolite levels or the calculated metabolite ratios was significantly different between the two study groups (p > 0.05). In the DPD deficient group all patients had at least one ).
PK analysis of u
lss Figure 6 .2 displays the correlation between the V max calculated with the EURMIX model for the LSS and full sampling for the subjects who underwent the FSS. The root mean square error and the mean prediction error were < 7.3% and < 1.8%, respectively showing that V max values calculated from the data of the limited sampling schedule are comparable to those calculated from the intensive sampling schedule. The V max values calculated with the EURMIX model based on the LSS time points in all subjects differed significantly between the two study groups (p < 0.001) as is shown in Figure 6 .3. Limited sampling strategy Chapter 6
toxicity data
There was no statistical difference observed in fluoropyrimidine specific cumulative toxicity, i.e. diarrhea, stomatitis, neutropenia and hand-foot, between the DPD normal and DPD deficient group (p = 0.495). Diarrhea was the most reported side effects in both study groups.
Chi square analysis revealed no significant difference in reported numbers of CTC grade I, II, III or IV toxicity and toxic side effects diarrhea, stomatitis, neutropenia and hand-foot syndrome between the two study groups (all p-values > 0.05). 300,00 400,00 500,00 600,00 700,00 800,00 900,00 1000,001100,00 
roc curves
The cut-off levels for V max,LSS value, U/DHU t=120min ratio and U t=120min concentrations were estimated by ROC analysis (Figure 6 .4). The data are displayed in Table 6 .3. For the U/DHU t=120min ratio, a cutoff level of 2.4 will result in a sensitivity of 80% and specificity of 98% with a positive predictive value of 67% and a negative predictive value of 99% to discriminate between subjects with normal DPD activity and DPD deficient subjects. The cut-off levels of V max,LSS and U t=120min showed lower specificity values when a sensitivity of 80% was chosen.
dIscussIon
In this study we developed a limited sampling model as a screening tool for DPD deficiency.
Several parameters were evaluated with respect to sensitivity and specificity of DPD deficiency. Based on our experience on the field of 5-FU pharmacokinetic modeling [7] we investigated the potential value of V max to interpretate U pharmacokinetics. The PK models for a DPD deficient population and DPD normal population revealed significant differences in V max which is in the deficient population 42% lower compared to a normal population. Despite this significant difference, there is an overlap in V max because of the Gaussion distribution within the population. This result is in line with the results of pharmacokinetic analysis of 5-FU plasma levels performed by van Kuilenburg et al [7] , and also with the fact that the mean DPD activity in patients heterozygous for a DPYD mutation is 48% of that observed in controls [7] . We validated the V max,LSS model by using LSS en FSS data employed in one population. This can be problematic because validation results and sensitivity/specificity values might be falsely influenced and elevated by this approach. Our validation involved only an explorative internal validation of the model in which each case is its own control. We realize that this should be followed by an external validation in which a different population should be used. There are two reasons that we did not perform this external validation. First, despite the fact that sensitivity and specificity results might be falsely influenced and elevated, the sensitivity and specificity are still lower compared to the U/DHU ratio. We consider it unlikely that external validation will result in higher sensitivity and specificity compared to U/DHU ratio. Secondly, to work with V max and PK modeling, highly sophisticated software and knowledge of PK are necessary and these are not present in every hospital. This latter issue means that V max is not a suitable candidate for use in a test performed in a prospective setting. The results of this study show that the U/DHU t=120 min ratio is superior to V max as a discriminating parameter. A possible explanation for this is that the calculated V max value is based on U plasma data only. DHU plasma data are not included in the model. Compared to a previous developed 5FU iv PK model [7] , the oral U PK model is more complex due to interindividual variability in bioavailability. Theoretically, the prediction of V max might improve when DHU data are included in a Michealis Menten PK model.
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The arrangement of the two study groups was based on the DPD activity in PBMCs. This enzymatic assay is influenced by factors such as lymphocyte, granulocyte and monocyte composition in peripheral blood and protein concentration. In this study however, we took into account all the potential pitfalls of this assay as identified before [11] . The results of the analysis in the present study did not identify any outliners in the study population. The power of the DPD activity assay in this study was further demonstrated by the fact that in the deficient group, pathogenic DPYD variants were detected in all subjects.
The study population concisted of patients with a history of severe toxicity while treated with 5-FU of capecitabine in order to enrich to DPD deficiency. The results can therefore only be interpreted for this population. Theoretically it is highly possible that patients in the DPD normal group might have varying degrees of DPD deficiency. This makes it difficult to apply the results to the general cancer population that also consists of patients without toxicity. Further research is needed in order to determine if the results of this study also apply to the general population. In this study we defined patients with a DPD activity in PBMCs The LSS strategy is an important improvement compared to the intensive sampling scheme that was used previously [9] and is more convenient for the patient. As the prevalence of a partial DPD deficiency in the general population is at least 3-5% [2] , a prospective test in order to detect deficiency has to be applied to a large number of patients to find those few individuals with a low DPD activity. We decided to choose a cut-off level for our test whereby the number of individuals with true positive results favours the number of individuals with false positive results. In a population of 1000 persons and an incidence of 5%, a sensitivity of 80% and a specificity of 98%, there will be 40 individuals with a true positive test result and 19 with a false positive test results, leading to a positive predictive value of 67%. As positive test cases are at risk of developing severe toxicity when fully dosed, we recommend that a dose reduction of 50% should at least be considered in line with the recommendations of the Royal Dutch Association for the Advancement of Pharmacy for DPYD genotyping [18] .
After an initial dose reduction and no toxicity, a dose escalation strategy could be followed in small steps based on clinical tolerability observed after each treatment cycle.
How do the results of this study compare with other strategies that are developed to detect DPD deficiency or prevent fluoropyrimidine related toxicity? There have been several genotyping studies in which sensitivity and specificity were established [19, 20] . It is difficult to compare our study results with these results, since these studies used different endpoints to the DPD activity that was used in our study. Only a head to head study would enable a fair comparison to be made between a genotyping and phenotyping strategy possible.
Compared to genotyping, an advantage of a phenotyping test strategies is that genetic variants outside the coding region of DPYD resulting in either a systemically altered DPD activity or altered 5-FU metabolism will be detected with these approaches. The incidence of these genetic variants however is very low as was proved by the fact that all subjects in the deficient group had variants inside the coding region of DPYD.
Among the included subjects, we identified one individual with a normal DPD activity in PBMCs of 8.3 nmol mg -1 *h -1 who had highly elevated U and DHU levels comparable to the other DPD deficient subjects. Mutation analysis of DPYD in this individual revealed the presence of the pathogenic c.1905+1G>A variant. Heterozygosity for this mutation, in combination with a low but normal DPD activity has been previously described before by van Kuilenburg et al [21] . Another individual included in the present study had a very low DPD activity in PBMCs of 1.0 nmol mg -1 *h -1 but the oral loading dose test results showed U and DHU considerably lower than the other DPD deficient subjects. Additional sequence analysis of DPYD in this case showed that there were no DPYD variants present. This observation was previously described by others investigators [8] . These two cases show that the results of the oral U loading test in these individuals correlated better with the results of genotyping than did the DPD activity in PBMCs which was used as the gold standard for inclusion in the present study.
It has been reported that homozygosity for mutant DPD alleles can lead to complete DPD deficiency resulting in elevated concentration of endogenous pyrimidine degradation metabolites [22] and neurologic disorders in children. In the present study, all patients were heterozygous for mutant DPD alleles and were only partial DPD deficient. Catabolism of the pyrimidine bases thymine and U consists of three consecutive steps [13] . The high concentrations of pyrimidine metabolites that accumulate in patients with a defect in 6 the enzyme responsible for pyrimdine degradation, compared with controls, could make identification of such patients feasible. DHU is not a metabolic end product but is further degraded into N-carbamyl-ß-alanine. In the present study, we found no statistical differences in the levels of any pyrimidine metabolites between the two study groups. Based on our results we see no beneficial effect of measuring these metabolites in heterozygous DPD deficient patients.
The U/DHU ratio at t = 2 hr after U ingestion appears to be an easy-to-calculate biomarker for predicting the U to DHU conversion rate, and can be implemented in daily practice of most hospitals. The HPLC equipment needed for the U and DHU assay is present in most hospitals laboratories or pharmacies. Based on our experience, we estimate that the cost prize of the oral U loading dose currently stands at around 110 Euros. Additional improvement in the test principle and assay could decrease this price further. A thorough cost-effectiveness analysis should be performed to establish total cost when this test is used in a prospective setting in all patients with an indication for fluoropyrimidine containing therapy. Based on our study results we conclude that the U/DHU ratio a t = 120 min following an oral U loading dose, is a suitable parameter for identifying patients at risk of developing severe toxicity as a result of DPD deficiency with a high sensitivity and specificity.
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